Comparing Dosage Adjustment Methods for Once-Daily Tobramycin in Paediatric and Adolescent Patients with Cystic Fibrosis

Clinical Pharmacokinetics

Volumn 54, Issue 4, 2015, Pages 409-421

  Hennig, Stefanie ^a   Holthouse, Franziska ^a   Staatz, Christine E ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

TOBRAMYCIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; AUSTRALIA; BAYESIAN LEARNING; CHILD; CONTROLLED STUDY; CYSTIC FIBROSIS; DATA ANALYSIS SOFTWARE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; FORECASTING; HUMAN; LOGLINEAR MODEL; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NOMOGRAM; PEDIATRIC HOSPITAL; PEDIATRICS; PHARMACOLOGICAL PARAMETERS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; VOLUME OF DISTRIBUTION; YOUNG ADULT; BAYES THEOREM; DOSE RESPONSE; DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PRESCHOOL CHILD; STATISTICAL MODEL;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BAYES THEOREM; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; LINEAR MODELS; MALE; NOMOGRAMS; RETROSPECTIVE STUDIES; TOBRAMYCIN;

EID: 84925517438     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0211-9     Document Type: Article

References (43)

1. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2009;(4):CD004197.
2. Wainwright C, Carlin J, Cooper P. Early infections with Pseudomonas can be cleared in young children with cystic fibrosis. Pediatr Pulm. 2002;S24:300.
3. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93–9.
4. Freeman CD, Nicolau DP, Belliveau PP, et al. Once-daily dosing of aminoglycosides: review and recommendations for clinical practice. J Antimicrob Chemother. 1997;39:667–86.
5. Touw DJ, Knox AJ, Smyth A. Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. J Cyst Fibros. 2007;6:327–33.
6. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin N Am. 2003;17:503–28 (v).
7. Karlowsky JA, Zhanel GG, Davidson RJ, et al. Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1994;38:1165–8.
8. Barclay ML, Duffull SB, Begg EJ, et al. Experience of once-daily aminoglycoside dosing using a target area under the concentration–time curve. Aust N Z J Med. 1995;25:230–5.
9. Paviour S, Hennig S, Staatz CE. Usage and monitoring of intravenous tobramycin in cystic fibrosis in Australia and the United Kingdom. In: 39th SHPA National Conference; Cairns; 2013.
10. Hennig S, Norris R, Kirkpatrick CM. Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis—a population pharmacokinetic study. Br J Clin Pharmacol. 2008;65:502–10.
11. Hennig S, Standing JF, Staatz CE, et al. Population pharmacokinetics of tobramycin in patients with and without cystic fibrosis. Clin Pharmacokinet. 2013;52:289–301.
12. Beringer PM, Vinks AA, Jelliffe RW, et al. Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration. Antimicrob Agents Chemother. 2000;44:809–13.
13. Levy J, Smith AL, Koup JR, et al. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study. J Pediatr. 1984;105:117–24.
14. Leeder JS, Spino M, Isles AF, et al. Ceftazidime disposition in acute and stable cystic fibrosis. Clin Pharmacol Ther. 1984;36:355–62.
15. Kearns GL, Hilman BC, Wilson JT. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis. J Pediatr. 1982;100:312–8.
16. Bulitta JB, Duffull SB, Kinzig-Schippers M, et al. Population pharmacokinetics and pharmacodynamics of piperacillin: systematic comparison of cystic fibrosis patients and healthy volunteers. Antimicrob Agents Chemother. 2007;51:2497–507.
17. Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother. 1995;39:650–5.
18. Avent ML, Teoh J, Lees J, et al. Comparing 3 methods of monitoring gentamicin concentrations in patients with febrile neutropenia. Ther Drug Monit. 2011;33:592–601.
19. Antibiotic Expert Group. Therapeutic guidelines: antibiotic. Version 12. Melbourne: Therapeutic Guidelines Ltd; 2003.
20. Massie J, Cranswick N. Pharmacokinetic profile of once daily intravenous tobramycin in children with cystic fibrosis. J Paediatr Child Health. 2006;42:601–5.
21. Sawchuk RJ, Zaske DE. Pharmacokinetics of dosing regimens which utilize multiple intravenous infusions: gentamicin in burn patients. J Pharmacokinet Biopharm. 1976;4:183–95.
22. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol. 1995;39:605–9.
23. Thomson AH, Whiting B. Bayesian parameter estimation and population pharmacokinetics. Clin Pharmacokinet. 1992;22:447–67.
24. Sheiner LB, Beal S, Rosenberg B, et al. Forecasting individual pharmacokinetics. Clin Pharmacol Ther. 1979;26:294–305.
25. Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J Pharm Sci. 1982;71:1344–8.
26. Xuan D, Lu JF, Nicolau DP, et al. Population pharmacokinetics of tobramycin in hospitalized patients receiving once-daily dosing regimen. Int J Antimicrob Agents. 2000;15:185–91.
27. de Hoog M, Schoemaker RC, Mouton JW, et al. Tobramycin population pharmacokinetics in neonates. Clin Pharmacol Ther. 1997;62:392–9.
28. Aarons L, Vozeh S, Wenk M, et al. Population pharmacokinetics of tobramycin. Br J Clin Pharmacol. 1989;28:305–14.
29. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503–12.
30. Holford NH, Buclin T. Safe and effective variability—a criterion for dose individualization. Ther Drug Monit. 2012;34:565–8.
31. Tod MM, Padoin C, Petitjean O. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods? Clin Pharmacokinet. 2001;40:803–14.
32. Mohan M, Batty KT, Cooper JA, et al. Comparison of gentamicin dose estimates derived from manual calculations, the Australian ‘Therapeutic Guidelines: Antibiotic’ nomogram and the SeBA-GEN and DoseCalc software programs. Br J Clin Pharmacol. 2004;58:521–7.
33. Alghanem S, Paterson I, Touw DJ, et al. Influence of multiple courses of therapy on aminoglycoside clearance in adult patients with cystic fibrosis. J Antimicrob Chemother. 2013;68:1338–47.
34. Aminimanizani A, Beringer PM, Kang J, et al. Distribution and elimination of tobramycin administered in single or multiple daily doses in adult patients with cystic fibrosis. J Antimicrob Chemother. 2002;50:553–9.
35. Campbell D, Thomson AH, Stack B. Population pharmacokinetics of aminoglycoside antibiotics in patients with cystic fibrosis. Ther Drug Monit. 1999;21:281–8.
36. Pai MP, Rodvold KA. Aminoglycoside dosing in patients by kidney function and area under the curve: the Sawchuk–Zaske dosing method revisited in the era of obesity. Diagn Microbiol Infect Dis. 2014;78:178–87.
37. Denaro CP, Ravenscroft PJ. Comparison of Sawchuk–Zaske and Bayesian forecasting for aminoglycosides in seriously ill patients. Br J Clin Pharmacol. 1989;28:37–44.
38. Hennig S, Nyberg J, Fanta S, et al. Application of the optimal design approach to improve a pretransplant drug dose finding design for ciclosporin. J Clin Pharmacol. 2012;52:347–60.
39. Duffull SB, Kirkpatrick CM, Begg EJ. Comparison of two Bayesian approaches to dose-individualization for once-daily aminoglycoside regimens. Br J Clin Pharmacol. 1997;43:125–35.
40. Burton ME, Brater DC, Chen PS, et al. A Bayesian feedback method of aminoglycoside dosing. Clin Pharmacol Ther. 1985;37:349–57.
41. Bottger HC, Oellerich M, Sybrecht GW. Use of aminoglycosides in critically ill patients: individualization of dosage using Bayesian statistics and pharmacokinetic principles. Ther Drug Monit. 1988;10:280–6.
42. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet. 2005;44:1051–65.
43. Schwartz GJ, Work DF. Measurement and estimation of GFR in children and adolescents. Clin J Am Soc Nephrol. 2009;4:1832–43.